6533b85efe1ef96bd12bf452

RESEARCH PRODUCT

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Guido KroemerOliver KeppFabrice AndrePatrick GüntherJose Manuel Bravo-san PedroThomas UlasSandy AdjemianSandy AdjemianElisa E. BaraccoAdele De NinnoGwenola ManicLuca BusinaroIlio VitaleValeria LucariniMonica LucattelliFederico PietrocolaSuzette DelalogeSuzette DelalogeLaurence ZitvogelYuting MaJoachim L. SchultzeMichaela SemeraroMichaela SemeraroGiovanna SchiavoniCeline LefebvreCeline LefebvreHeng YangKariman ChabaLionel ApetohAntonella SistiguSylvain LadoireGautier StollChristophe BorgDavid EnotValérie BoigeValérie BoigeMichel DucreuxMichel DucreuxFrancesca CastoldiFrancesca PeschiaroliFabrizio MatteiSylvie RusakiewiczSylvie RusakiewiczErika VacchelliCécile DelarasseMichele SignoreAnnamaria GerardinoClaire MulotClaire MulotPierre Laurent-puigPierre Laurent-puig

subject

AnthracyclineColorectal cancermedicine.medical_treatmentT-LymphocytesBreast Neoplasmsmicrofluidic chipchemotherapyPolymorphism Single NucleotideFormyl peptide receptor 1immune responseMiceImmune systemImmunityCell Line TumorNeoplasmsmedicineLeukocytesAnimalsHumansAnthracyclinesAllelesAnnexin A1ChemotherapyMultidisciplinarybusiness.industryDendritic Cellsmedicine.diseaseReceptors Formyl PeptideImmunity InnateChemotherapy AdjuvantCancer cellImmunologyCancer researchFemalebusinessColorectal NeoplasmsAdjuvantFPR1 microfluidic

description

How dying tumor cells get noticed Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972

yearjournalcountryeditionlanguage
2015-01-01Science (New York, N.Y.)
10.1126/science.aad0779https://pubmed.ncbi.nlm.nih.gov/26678335